Aug 08, 2022 4:30pm EDT Sutro Biopharma Reports Second Quarter 2022 Financial Results, Business Highlights and Anticipated Milestones
Jul 26, 2022 4:01pm EDT Sutro Biopharma Achieves “First in Human” Milestone in Cytokine Derivatives Collaboration with Merck
Jul 12, 2022 7:00am EDT Sutro Biopharma Announces Virtual Deep Dive Research Forum: Next-Gen Innovations in ADCs
Jun 27, 2022 7:31pm EDT Astellas and Sutro Biopharma Announce Worldwide Strategic Collaboration to Advance Novel Immunostimulatory Antibody-Drug Conjugates (iADCs)
Jun 03, 2022 4:01pm EDT Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 09, 2022 4:30pm EDT Sutro Biopharma Reports First Quarter 2022 Financial Results, Business Highlights, and Anticipated Milestones
Apr 29, 2022 5:00pm EDT Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apr 08, 2022 1:00pm EDT Sutro Biopharma Presents Nonclinical Data for Antibody-Drug Conjugate STRO-002 at the AACR Annual Meeting 2022